Why Eli Lilly Stock Jumped to a Record High on Tuesday

Key TakeawaysA three-year study of tirzepatide—the active ingredient in Eli Lilly's injectable weight-loss drug Zepbound and diabetes treatment Mounjaro—showed a 94% reduction in type 2 diabetes progression risk compared to a placebo.Patients who received tirzepatide lost 22.9% of their body weight on average, compared with 2.1% for patients who received a placebo.Eli Lilly shares jumped to an all-time high on Tuesday, bringing their year-to-date return to more than 60%. Eli Lilly (LLY) stock jumped to a re ...